ACM

At ACM Biolabs, we are focused on developing novel vaccines and antibodies using our proprietary artificial cell membrane ("ACM"​) technology. We are able to incorporate functional, folded membrane proteins into the artificial cell membranes which keep them stable, allowing them to induce a strong immune reaction. We have demonstrated efficacy via both injected and oral dosages using synthesized membrane proteins and have a growing pipeline of vaccine and antibodies. The company is headquartered in Singapore, and has been operational since 2013.